NCT07109986View on ClinicalTrials.gov

UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

May 8, 2028

Study Completion Date

July 8, 2030

Conditions
Systemic Lupus ErythematosusLupus Nephritis
Interventions
DRUG

UB-VV410

Treatment with single dose of UB-VV410, intravenous injection at Day 1. Note: Subjects may receive retreatment with UB-VV410 if there are preliminary findings suggesting incomplete improvement and acceptable safety.

All Listed Sponsors
collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

lead

Nanjing IASO Biotechnology Co., Ltd.

INDUSTRY